267 related articles for article (PubMed ID: 33511412)
1. Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition.
Ogden TEH; Yang JC; Schimpl M; Easton LE; Underwood E; Rawlins PB; McCauley MM; Langelier MF; Pascal JM; Embrey KJ; Neuhaus D
Nucleic Acids Res; 2021 Feb; 49(4):2266-2288. PubMed ID: 33511412
[TBL] [Abstract][Full Text] [Related]
2. Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery.
Rouleau-Turcotte É; Krastev DB; Pettitt SJ; Lord CJ; Pascal JM
Mol Cell; 2022 Aug; 82(16):2939-2951.e5. PubMed ID: 35793673
[TBL] [Abstract][Full Text] [Related]
3. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
4. Structural basis for allosteric PARP-1 retention on DNA breaks.
Zandarashvili L; Langelier MF; Velagapudi UK; Hancock MA; Steffen JD; Billur R; Hannan ZM; Wicks AJ; Krastev DB; Pettitt SJ; Lord CJ; Talele TT; Pascal JM; Black BE
Science; 2020 Apr; 368(6486):. PubMed ID: 32241924
[TBL] [Abstract][Full Text] [Related]
5. Fluorescent sensors of PARP-1 structural dynamics and allosteric regulation in response to DNA damage.
Steffen JD; McCauley MM; Pascal JM
Nucleic Acids Res; 2016 Nov; 44(20):9771-9783. PubMed ID: 27530425
[TBL] [Abstract][Full Text] [Related]
6. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1.
Eustermann S; Wu WF; Langelier MF; Yang JC; Easton LE; Riccio AA; Pascal JM; Neuhaus D
Mol Cell; 2015 Dec; 60(5):742-754. PubMed ID: 26626479
[TBL] [Abstract][Full Text] [Related]
7. Unraveling the allosteric inhibition mechanism of PARP-1 CAT and the D766/770A mutation effects via Gaussian accelerated molecular dynamics and Markov state model.
Wang Q; Zhang M; Li A; Yao X; Chen Y
Comput Biol Med; 2024 Jan; 168():107682. PubMed ID: 38000246
[TBL] [Abstract][Full Text] [Related]
8. PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain.
Dawicki-McKenna JM; Langelier MF; DeNizio JE; Riccio AA; Cao CD; Karch KR; McCauley M; Steffen JD; Black BE; Pascal JM
Mol Cell; 2015 Dec; 60(5):755-768. PubMed ID: 26626480
[TBL] [Abstract][Full Text] [Related]
9. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine.
Nilov D; Maluchenko N; Kurgina T; Pushkarev S; Lys A; Kutuzov M; Gerasimova N; Feofanov A; Švedas V; Lavrik O; Studitsky VM
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245127
[TBL] [Abstract][Full Text] [Related]
10. Free energy calculation provides insight into the action mechanism of selective PARP-1 inhibitor.
Cao R
J Mol Model; 2016 Apr; 22(4):74. PubMed ID: 26969680
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1.
Langelier MF; Planck JL; Roy S; Pascal JM
Science; 2012 May; 336(6082):728-32. PubMed ID: 22582261
[TBL] [Abstract][Full Text] [Related]
12. NAD
Langelier MF; Zandarashvili L; Aguiar PM; Black BE; Pascal JM
Nat Commun; 2018 Feb; 9(1):844. PubMed ID: 29487285
[TBL] [Abstract][Full Text] [Related]
13. A Poly-ADP-Ribose Trigger Releases the Auto-Inhibition of a Chromatin Remodeling Oncogene.
Singh HR; Nardozza AP; Möller IR; Knobloch G; Kistemaker HAV; Hassler M; Harrer N; Blessing C; Eustermann S; Kotthoff C; Huet S; Mueller-Planitz F; Filippov DV; Timinszky G; Rand KD; Ladurner AG
Mol Cell; 2017 Dec; 68(5):860-871.e7. PubMed ID: 29220653
[TBL] [Abstract][Full Text] [Related]
14. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic insight into the role of Poly(ADP-ribosyl)ation in DNA topology modulation and response to DNA damage.
Matkarimov BT; Zharkov DO; Saparbaev MK
Mutagenesis; 2020 Feb; 35(1):107-118. PubMed ID: 31782485
[TBL] [Abstract][Full Text] [Related]
16. Modeling of the Enzyme-Substrate Complexes of Human Poly(ADP-Ribose) Polymerase 1.
Nilov DK; Pushkarev SV; Gushchina IV; Manasaryan GA; Kirsanov KI; Švedas VK
Biochemistry (Mosc); 2020 Jan; 85(1):99-107. PubMed ID: 32079521
[TBL] [Abstract][Full Text] [Related]
17. Structure-based design of new poly (ADP-ribose) polymerase (PARP-1) inhibitors.
Chadha N; Jaggi AS; Silakari O
Mol Divers; 2017 Aug; 21(3):655-660. PubMed ID: 28653128
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
19. PARP-2 and PARP-3 are selectively activated by 5' phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1.
Langelier MF; Riccio AA; Pascal JM
Nucleic Acids Res; 2014 Jul; 42(12):7762-75. PubMed ID: 24928857
[TBL] [Abstract][Full Text] [Related]
20. BTH-8, a novel poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor, causes DNA double-strand breaks and exhibits anticancer activities in vitro and in vivo.
Guo C; Zhang F; Wu X; Yu X; Wu X; Shi D; Wang L
Int J Biol Macromol; 2020 May; 150():238-245. PubMed ID: 32057845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
